k13

K-13 is used as an ACE inhibitor produced by Micromonospora halophytics subsp. exilisia K-13.

K 13-004 is a lipid-lowering agent.

GSK137647A (GSK 137647) is a selective agonist of FFA4.

GSK1379725A is a selective BPTF ligand [Kd = 2.8 μM].

G13KS is a deubiquitinase UCHL1 ligand and inhibitor that reduces levels of monoubiquitin in human glioblastoma cells by inhibiting both recombinant and cellular UCHL1 [1].

Anti-Mouse NK1.1 Antibody (PK136) is an IgG2a class antibody of murine origin targeting NK1.1, which eliminates NK1.1 and NK1.1NKT cells and inhibits NK1.1 signaling in peripheral blood, spleen, and lung tissues, and can be used in the study of heart and lung failure.

GSK1370319A is a potent P2X7 antagonist (IC50 = 3.2 nM). GSK1370319A inhibits ATP-induced increase in IL-1β release and caspase 1 activation in lipopolysaccharide (LPS)-primed mixed glia by blocking assembly of the inflammasome in a pannexin 1-dependent manner. GSK1370319A also inhibits ATP-induced subregion-specific neuronal loss in hippocampal organotypic slice cultures, which is dependent on its ability to prevent inflammasome assembly in glia. Significantly, GSK1370319A attenuates age-related deficits in long-term potentiation (LTP) and inhibits the accompanying age-related caspase 1 activity. We conclude that inhibiting P2X(7) receptor-activated NLRP3 inflammasome formation and the consequent IL-1β release from glia preserve neuronal viability and synaptic activity.

GSK1360707 is a selective triple reuptake inhibitor (TRI).

GSK1324726A (I-BET726) is a greatly specific inhibitor of BET family proteins for BRD2(IC50=41 nM), BRD3(IC50=31 nM), and BRD4 (IC50=22 nM).

MAPK13-IN-1 is a potent MAPK13 (p38δ) inhibitor (IC50: 620 nM).

GSK1379767A is a dual inhibitor of BPTF and Brd4.

K134 is an inhibitor of phosphodiesterase 3. The IC50s of K134 for PDE3A, PDE3B, PDE5, PDE2 and PDE4 are 0.1, 0.28, 12.1, >300 and >300 μM, respectively.